In a release issued earlier
today by Biodel Inc. BIOD, one reference to BIOD-238 should have been
BIOD-250 in the fourth paragraph. The corrected paragraph follows:
Local injection site discomfort was measured with a 100 mm visual analog scale
(VAS) and patient questionnaires. 100 mm is defined as the worst possible
discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS
score was numerically lower, but not significantly different for BIOD-250
compared to Humalog^® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and
Humalog^®, respectively; p=NS). The VAS score for BIOD-238 was significantly
higher than that associated with Humalog^® (mean VAS score of 24.2 mm, p=0.029
vs. Humalog^®).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in